Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Ian Fraser Appointed as EVP Clinical Development
Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech […]
Optellum Attains CE Marking for Its Early Lung Cancer Diagnosis AI Technology
Optellum, an Oxford-based medtech company that provides breakthrough AI technologies to help with early diagnosis of […]
Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III SKYSCRAPER-02 study, evaluating the […]
NHS Comment On Study Linking Type 2 Diabetes To Earlier Health Problems
Comment from Professor Jonathan Valabhji on a new study from the University of Cambridge, that […]
John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer
John Theurer Cancer Center at Hackensack University Medical Center, New Jersey’s top ranked cancer center, according to U.S. […]
XNK Therapeutics Raises SEK 132 Million to Accelerate Growth
XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, […]
Seekyo Adds Diagnostics and Theranostics Capabilities to Its Lead Compound SKY01 That Targets Solid Tumors
Seekyo, a startup specializing in developing smart chemotherapy drugs, today announces the availability of personalized […]
Innovent and Lilly Expand Strategic Partnership in Oncology
Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes […]
Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted […]
Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer
Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more